TUCSON, Ariz., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today announced that Matt Schuster, Chief Operating Officer, will present an update on the Company’s fully implantable total artificial heart technology as part of the DeviceTalks Tuesdays webcast series hosted by DeviceTalks. During the session, Mr. S ...

Core Viewpoint - Picard Medical, Inc. is actively participating in key healthcare conferences, highlighting its leadership in total artificial heart technology and its commitment to advancing medical innovation [1][4]. Group 1: Conference Participation - Picard Medical will attend the 44th Annual J.P. Morgan Healthcare Conference, including events such as LifeSci Advisors' Corporate Access Event and Lifeblood and Goodwin's CEO-Only MedTech Forum [1]. - The Lifeblood and Goodwin's MedTech CEO-Only Forum is scheduled for January 12, 2026, as an invite-only discussion forum in San Francisco, CA [3]. - The LifeSci Advisors 15th Annual Corporate Access Event will take place on January 14, 2026, featuring one-on-one meetings at The Beacon Grand, San Francisco, CA [3]. Group 2: Company Overview - Picard Medical, Inc. is the parent company of SynCardia Systems, LLC, which is recognized for its SynCardia Total Artificial Heart (STAH), the only commercially available total artificial heart technology for patients with end-stage heart failure [4]. - The SynCardia Total Artificial Heart is the first artificial heart approved by both the FDA and Health Canada, and it is the only commercially available artificial heart in the United States and Canada [4]. - Over 2,100 implants of the SynCardia Total Artificial Heart have been performed in hospitals across 27 countries, making it the most widely used and extensively studied artificial heart globally [4].

Core Insights - Picard Medical, Inc. has announced the election of Patrick NJ Schnegelsberg as a member of the Board of Directors of the Arizona Bioindustry Association (AZBio), with his term extending through December 2028 [1][2] Company Overview - Picard Medical is the parent company of SynCardia Systems, which is known for developing the world's first total artificial heart approved by both the U.S. FDA and Health Canada [1][5] - The SynCardia Total Artificial Heart (STAH) is the only commercially available artificial heart in the U.S. and Canada, with over 2,100 implants performed across 27 countries, making it the most widely used and studied artificial heart globally [5] Industry Context - Arizona is recognized as a significant hub for life sciences innovation, with AZBio playing a crucial role in fostering collaboration and growth within the industry [2][4] - The AZBio Association aims to promote the growth of Arizona bioscience companies and serves as a unified voice for the bioscience industry in the state [4]

Core Viewpoint - Picard Medical, Inc. has announced a definitive agreement for a private placement financing of up to $50 million in senior secured notes due 2028, along with warrants for common stock purchase [1][2]. Group 1: Financing Details - The company plans to issue an initial $15 million principal amount of notes at closing, with an option to fund an additional $35 million in one or more tranches, subject to certain conditions [2]. - The notes will be senior secured obligations of the company, indicating a priority claim on assets in case of liquidation [2]. Group 2: Use of Proceeds - The net proceeds from this financing will be utilized for working capital and general corporate purposes [2]. Group 3: Company Overview - Picard Medical, Inc. is the parent company of SynCardia Systems, LLC, which is known for its SynCardia Total Artificial Heart, the first artificial heart approved by both the U.S. FDA and Health Canada [4]. - SynCardia's technology is the only commercially available total artificial heart for patients with end-stage heart failure, with over 2,100 implants performed across 27 countries, making it the most widely used artificial heart globally [4].

Core Viewpoint - Picard Medical, Inc. has transitioned to public markets and is committed to advancing its Total Artificial Heart technology for patients with end-stage heart failure [1][2]. Company Overview - Picard Medical, Inc. is the parent company of SynCardia Systems, LLC, which is based in Tucson, Arizona and is the leader in total artificial heart technology for end-stage heart failure patients [3]. - SynCardia has developed the SynCardia Total Artificial Heart (STAH), the first artificial heart approved by both the FDA and Health Canada, and remains the only commercially available artificial heart in the U.S. and Canada [3]. - Over 2,100 implants of the SynCardia Total Artificial Heart have been performed in hospitals across 27 countries, making it the most widely used and studied artificial heart globally [3]. Transition to Public Markets - The company will ring the Opening Bell at the New York Stock Exchange on December 18, 2025, marking its transition to being a publicly traded entity [1]. - The CEO of Picard Medical expressed pride in this transition, emphasizing that it strengthens the company's ability to advance its artificial heart platform, including the fully implantable Emperor system [2]. Future Outlook - The transition to a public company is seen as an important phase for Picard Medical, as it aims to build on decades of clinical leadership and create long-term value through the advancement of next-generation technology [2].

Core Insights - Picard Medical, Inc. is the parent company of SynCardia Systems LLC, which produces the world's first total artificial heart approved by both the U.S. FDA and Health Canada [1][3] - CEO Patrick NJ Schnegelsberg will present data on the Emperor Total Artificial Heart at the CSI Focus D-HF conference in Frankfurt, Germany, on December 6, 2025 [1][2] Company Overview - Picard Medical, Inc. is based in Tucson, Arizona, and is a leader in total artificial heart technology for patients with end-stage heart failure [3] - The SynCardia Total Artificial Heart (STAH) is the only commercially available artificial heart in the U.S. and Canada, having been implanted over 2,100 times across 27 countries, making it the most widely used and studied artificial heart globally [3]

Core Viewpoint - Picard Medical, Inc. will present in vitro data on its fully implantable Emperor Total Artificial Heart at the ISMCS 2025 conference, highlighting advancements in patient mobility and quality of life [1][3]. Group 1: Presentation Details - The presentation is scheduled for December 4, 2025, at 14:05 CET during the Mini Oral Session 3 focused on Hemocompatibility and Heart/Pump Interaction [2]. - The title of the presentation is "The Emperor Total Artificial Heart: A Next Generation, Fully Implantable Total Artificial Heart," and it will be presented by Duffy Elmer, Engineering Project Manager at Picard Medical [2]. Group 2: Product Information - The Emperor Total Artificial Heart features an internal motor-driven design that eliminates the need for an external pneumatic driver, aiming to enhance patient mobility and overall quality of life [3]. - Picard Medical, through its subsidiary SynCardia Systems, is the only company with commercially available total artificial heart technology for patients with end-stage heart failure, having performed over 2,100 implants across 27 countries [5]. Group 3: Event Information - ISMCS 2025 is the 31st annual global congress of the International Society for Mechanical Circulatory Support, bringing together various stakeholders to discuss new clinical research and emerging technologies in mechanical circulatory support [4].

Core Insights - Picard Medical, Inc. successfully completed its initial public offering (IPO) on September 2, 2025, raising approximately $19.5 million in gross proceeds, which will be used to strengthen its balance sheet and accelerate research and development [4][7]. Financial Performance - Third quarter revenue reached $1.19 million, a 35% increase from the same period in 2024, driven by higher U.S. product sales and increased driver rentals [5]. - The cost of revenue declined by 15% year-over-year, resulting in a gross loss reduction of 81% to $0.13 million [5]. - Operating expenses decreased by 11% to $3.36 million, leading to a narrowed operating loss of $3.36 million compared to $3.77 million in Q3 2024 [6]. - For the nine-month period ending September 30, 2025, revenue totaled $3.93 million, an 11% increase from 2024, while the operating loss remained consistent at $10.3 million [7]. Strategic Developments - The company secured additional patent protection for its SynCardia Total Artificial Heart (STAH), reinforcing its commitment to life-saving technology [3]. - Two independent directors, Sam Van and George Ye, were appointed to the board to provide leadership and guidance as the company transitions to a public entity [3][7]. - A new patent (U.S. Patent No. 12,383,722 B2) was granted for the next-generation fully implantable SynCardia Total Artificial Heart, expanding the company's intellectual property portfolio [7]. Market Position - Picard Medical, through its subsidiary SynCardia, is the only company with commercially available total artificial heart technology for patients with end-stage heart failure, with over 2,100 implants performed globally [10].

Company Overview - Picard Medical, Inc. is the parent company of SynCardia Systems, LLC, which is the leader in total artificial heart technology for patients with end-stage heart failure [3] - SynCardia's Total Artificial Heart (STAH) is the first artificial heart approved by both the U.S. FDA and Health Canada, and it is the only commercially available artificial heart in the United States and Canada [3] - Over 2,100 implants of the SynCardia Total Artificial Heart have been performed in hospitals across 27 countries, making it the most widely used and extensively studied artificial heart globally [3] Upcoming Events - Picard Medical will attend the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 20, 2025, in New York, NY [1] - Patrick NJ Schnegelsberg, CEO of Picard Medical, will be available for one-on-one meetings with investors during the event [2]

Core Viewpoint - Picard Medical, Inc. has stated that it is not aware of any undisclosed material changes in its operations or financial condition that would explain the recent volatility in its stock price [1] Company Overview - Picard Medical, Inc. is the parent company of SynCardia Systems, LLC, which is the only provider of commercially available total artificial heart technology for patients with end-stage heart failure [3] - The SynCardia Total Artificial Heart (STAH) is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada [3] - Over 2,100 implants of the SynCardia Total Artificial Heart have been performed in hospitals across 27 countries, making it the most widely used and extensively studied artificial heart globally [3] Strategic Focus - The company remains committed to executing its strategic and operational priorities while ensuring compliance with all disclosure obligations under applicable securities laws [2]